GameChangers: Updated Alcohol Abuse Guidelines

GameChangers: Updated Alcohol Abuse Guidelines

Alcohol Use Disorder (AUD) and cirrhosis are common medical conditions with significant morbidity and mortality. Join host, Geoff Wall, as he evaluates the new American College of Gastroenterology guidelines.

THE GAMECHANGER: The MELD score is now preferred over the Madrey score for assessing mortality. Baclofen is the primary treatment for reducing consumption and craving in alcohol use disorder.

Upon successful completion of this course, learners should be able to:
1. Discuss the initial treatment of a patient admitted with acute alcoholic hepatitis
2. Describe a pharmacotherapeutic plan for adjunctive treatment of alcohol use disorder

Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.  

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: January 22, 2024
Planned Expiration Date: January 22, 2025

Copyright 2024, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

Universal Activity Number (UAN): 0107-0000-24-042-H01-P
Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information


0h 30m

Topic Designator

Disease State/Drug Therapy



ACPE Topic

01 Drug Therapy





Release Date






ACPE Number


This course is in our subscription.